Poolbeg Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jeremy Skillington

İcra Kurulu Başkanı

UK£362.0k

Toplam tazminat

CEO maaş yüzdesi	69.1%
CEO görev süresi	3.3yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Jeremy Skillington'un ücretlendirmesi Poolbeg Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-UK£4m
Mar 31 2024	n/a	n/a	-UK£4m
Dec 31 2023	UK£362k	UK£250k	-UK£4m
Sep 30 2023	n/a	n/a	-UK£4m
Jun 30 2023	n/a	n/a	-UK£5m
Mar 31 2023	n/a	n/a	-UK£5m
Dec 31 2022	UK£310k	UK£250k	-UK£5m
Dec 31 2021	UK£261k	n/a	-UK£3m

Tazminat ve Piyasa: Jeremy 'ın toplam tazminatı ($USD 454.60K ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 474.54K ).

Tazminat ve Kazançlar: Jeremy şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jeremy Skillington (53 yo)

3.3yrs

Görev süresi

UK£362,000

Tazminat

Dr. Jeremy Skillington, Ph D., serves as Chief Executive Officer and since July 19, 2021 as Director at Poolbeg Pharma PLC. He is Vice President of Business Development at Inflazome Ltd.Dr. Skillington se...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Cathal Friel	Executive Chairman of The Board	3.7yrs	UK£150.00k	4.36% € 1.9m
Jeremy Skillington	CEO & Director	no data	UK£362.00k	0.17% € 75.9k
Ian O'Connell	CFO & Director	no data	UK£237.00k	1.67% € 723.6k
Carol Dalton	Vice President of Investor Relations & Public Relations	1.8yrs	Veri yok	Veri yok
John McEvoy	Senior Vice President & Chief Legal Officer	less than a year	Veri yok	Veri yok
David Allmond	Chief Business Officer	less than a year	Veri yok	Veri yok
Ross Crockett	Group Financial Controller	no data	Veri yok	Veri yok

0.9yrs

Ortalama Görev Süresi

53.5yo

Ortalama Yaş

Deneyimli Yönetim: 7JN 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.9 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Cathal Friel	Executive Chairman of The Board	3.7yrs	UK£150.00k	4.36% € 1.9m
Jeremy Skillington	CEO & Director	3.3yrs	UK£362.00k	0.17% € 75.9k
Ian O'Connell	CFO & Director	3.5yrs	UK£237.00k	1.67% € 723.6k
Luke O'Neill	Independent Non-Executive Director & Member of Scientific Advisory Board	3.3yrs	UK£40.00k	Veri yok
Brendan Buckley	Member of Scientific Advisory Board & Independent Non Executive Director	1.9yrs	UK£24.00k	0.53% € 228.7k
Elaine Sullivan	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Edward Gibson	Senior Independent Director	3.3yrs	UK£35.00k	Veri yok
Daniel Hoft	Member of Scientific Advisory Board	3yrs	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 7JN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Poolbeg Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Poolbeg Pharma PLC, Annual General Meeting, Jun 13, 2024

Executive Chairman of The Board recently bought €113k worth of stock

Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman

High number of new and inexperienced directors

Poolbeg Pharma plc Announces Directorate Changes

Poolbeg Pharma plc Announces Executive Appointments

Recent updates

Poolbeg Pharma plc Announces U.S. Patent Office Grants U.S. Immunomodulator I Patent

Poolbeg Pharma Announces Voluntary Delist from OTCQB Market

Poolbeg Pharma PLC, Annual General Meeting, Jun 13, 2024

Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application

New minor risk - Financial data availability

Executive Chairman of The Board recently bought €113k worth of stock

Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman

Independent Research Confirms >$10 Billion Market Opportunity for POLB 001 as A Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)

Poolbeg Pharma plc Further Data Confirms Polb 001'S Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome

High number of new and inexperienced directors

Poolbeg Pharma plc Announces Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV Drug Candidates with the High Probability of Successful Successful Successfully

Poolbeg Pharma plc Announces Key Insights from Its Poster Presentation at ASH POLB 001

Poolbeg Pharma plc Announces Directorate Changes

Poolbeg Pharma plc Announces Executive Appointments

Poolbeg Pharma plc Announces Scientific Advisory Board Endorses Influenza Drug Targets Identified in Ai Drug Discovery Programme

Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition

Poolbeg Pharma Receives Notice of Allowance from the Japanese Patent Office in Relation to its Immunomodulator I Patent Application

Poolbeg Pharma plc Announces Immunomodulator I Patent Opposition Withdrawal

Poolbeg Pharma plc Announces Significant Breakthrough in Its World First Influenza Artificial Intelligence Programme with Cytoreason

Less than half of directors are independent

Poolbeg Pharma PLC Announces Board Changes

Poolbeg Pharma plc Announces Strategic Expansion of Polb 001 into Oncology

Poolbeg Pharma PLC Announces Positive Initial Data Analysis in POLB 001 Trial

Poolbeg Pharma Identifies Novel RSV Drug Candidates

Poolbeg Pharma plc Announces POLB 001 LPS Human Challenge Clinical Trial Successfully Completed

Poolbeg Pharma Announces Completion of Influenza AI Model Build

Poolbeg Pharma PLC to Report First Half, 2022 Results on Sep 06, 2022

Poolbeg Pharma plc Receives Ethics and Competent Authority Approval to Commence Its Lipopolysaccharide (Lps) Human Challenge Clinical Trial for Polb 00

Poolbeg Pharma plc Provides Project Update for AI Model of RSV Data

Poolbeg Pharma PLC Provides Update on POLB 001 Clinical Development

No independent directors

Poolbeg Pharma plc Provides an Update on the Strengthening of Its Intellectual Property for Its Asset POLB 002

Poolbeg Pharma PLC to Report Q4, 2021 Results on Mar 03, 2022

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş